SOD1 and amyotrophic lateral sclerosis: Thus far, most ALS AAV vector therapies tested pre-clinically target mutant SOD1. Several groups have demonstrated the effective therapeutic potential of using AAV vectors to deliver miRNA or shRNA targeting mutant SOD1 in SOD1G93A rat and mouse models40–44.